Lumefantrine
- Generic Name
- Lumefantrine
- Brand Names
- Coartem
- Drug Type
- Small Molecule
- Chemical Formula
- C30H32Cl3NO
- CAS Number
- 82186-77-4
- Unique Ingredient Identifier
- F38R0JR742
- Background
Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas.
- Indication
Lumefantrine and artemether combination therapy is indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including malaria acquired in chloroquine-resistant areas. May also be used to treat uncomplicated malaria when the Plasmodium species has not been identified. Indicated for use in adults and children greater than 5 kg.
- Associated Conditions
- Uncomplicated Malaria caused by Plasmodium falciparum
Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria
- Conditions
- Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT05842954
- Locations
- 🇿🇲
Novartis Investigative Site, Ndola, Zambia
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 252
- Registration Number
- NCT04675931
- Locations
- 🇺🇬
Novartis Investigative Site, Tororo, Uganda
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
- Conditions
- Malaria,Falciparum
- Interventions
- Drug: Artesunate-amodiaquine combination
- First Posted Date
- 2020-09-25
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- University of Yaounde 1
- Target Recruit Count
- 242
- Registration Number
- NCT04565184
- Locations
- 🇨🇲
District Medical Center Minkoa Meyos, Yaoundé, Center, Cameroon
Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 295
- Registration Number
- NCT04546633
- Locations
- 🇲🇱
Novartis Investigative Site, Sotuba, Mali
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ Challenge
- First Posted Date
- 2019-05-16
- Last Posted Date
- 2022-07-12
- Target Recruit Count
- 252
- Registration Number
- NCT03952650
- Locations
- 🇲🇱
Malaria Vaccine Center STTB/MRTC, Bamako, Mali
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 188
- Registration Number
- NCT03334747
- Locations
- 🇺🇬
Novartis Investigative Site, Tororo, Uganda
Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
- Conditions
- Acute Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2017-05-25
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 524
- Registration Number
- NCT03167242
- Locations
- 🇻🇳
Novartis Investigative Site, Binh Phuoc Province, VNM, Vietnam
Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali
- Conditions
- Malaria
- Interventions
- Biological: Pfs25M-EPAOther: AS01Other: Normal Saline
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 301
- Registration Number
- NCT02942277
- Locations
- 🇲🇱
Bancoumana Malaria Vaccine Center, Bamako, Mali
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites in Healthy African Adults in Mali
- Conditions
- Malaria
- Interventions
- Biological: PfSPZ VaccineBiological: PfSPZ Challenge MaterialOther: Normal SalineDrug: PBS and HSA Diluent
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2021-04-21
- Target Recruit Count
- 409
- Registration Number
- NCT02627456
- Locations
- 🇲🇱
University of Bamako (USTTB/MRTC), Bamako, Mali
Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Albert Schweitzer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT02528279
- Locations
- 🇬🇦
Centre de Recherches Médicales de Lambaréné, Hôpital Albert Schweitzer, Lambaréné, Moyen-Ogooué, Gabon
🇬🇦Centre de Recherches Médicales de Ngounié, Fougamou, Ngounié, Gabon
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.